X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (632) 632
Publication (48) 48
Magazine Article (46) 46
Book Review (20) 20
Book Chapter (19) 19
Trade Publication Article (16) 16
Newspaper Article (8) 8
Book / eBook (5) 5
Conference Proceeding (5) 5
Government Document (5) 5
Newsletter (4) 4
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (421) 421
index medicus (312) 312
biosimilar pharmaceuticals - economics (232) 232
biosimilar pharmaceuticals - therapeutic use (210) 210
biosimilars (195) 195
biosimilar pharmaceuticals (174) 174
biological products (172) 172
biosimilar (136) 136
united states (130) 130
pharmacology & pharmacy (117) 117
pharmaceutical industry (111) 111
drug approval (96) 96
safety (90) 90
drugs (84) 84
infliximab (82) 82
oncology (78) 78
generic drugs (75) 75
europe (74) 74
double-blind (69) 69
drug costs (68) 68
biosimilar pharmaceuticals - adverse effects (65) 65
biologics (64) 64
female (63) 63
fda approval (61) 61
animals (60) 60
rheumatology (59) 59
treatment outcome (58) 58
male (56) 56
efficacy (55) 55
rheumatoid arthritis (52) 52
antibodies, monoclonal - therapeutic use (51) 51
biosimilar pharmaceuticals - administration & dosage (51) 51
laws, regulations and rules (51) 51
monoclonal antibodies (49) 49
patients (49) 49
research (49) 49
therapeutic equivalency (49) 49
ct-p13 (48) 48
immunogenicity (48) 48
neoplasms - drug therapy (47) 47
united states food and drug administration (47) 47
innovator infliximab (46) 46
analysis (45) 45
parallel-group (45) 45
adult (44) 44
cost-benefit analysis (44) 44
medicine, general & internal (44) 44
studies (44) 44
cancer (43) 43
cost control (43) 43
medicine (42) 42
middle aged (42) 42
medicine, research & experimental (41) 41
review (41) 41
arthritis (40) 40
drug approval - legislation & jurisprudence (40) 40
health care sciences & services (40) 40
biological products - economics (39) 39
drugs, generic - economics (38) 38
infliximab - therapeutic use (38) 38
antibodies (37) 37
antirheumatic agents - therapeutic use (37) 37
biotechnology & applied microbiology (37) 37
health policy & services (37) 37
medicine & public health (37) 37
pharmacology (37) 37
usage (37) 37
biosimilar pharmaceuticals - standards (36) 36
biotechnology (36) 36
cost savings (36) 36
biosimilar pharmaceuticals - pharmacology (35) 35
drug therapy (35) 35
economic aspects (35) 35
manufacturing (35) 35
chemotherapy (34) 34
aged (33) 33
arthritis, rheumatoid - drug therapy (33) 33
clinical trials (33) 33
competition (33) 33
interchangeability (33) 33
economics (32) 32
filgrastim (32) 32
immunology (32) 32
pharmaceuticals (32) 32
antibodies, monoclonal - economics (31) 31
patents as topic (31) 31
pharmacovigilance (31) 31
rheumatoid-arthritis (31) 31
care and treatment (30) 30
drug industry - economics (30) 30
forecasts and trends (30) 30
biological products - therapeutic use (28) 28
european union (28) 28
patents (28) 28
public health (28) 28
biopharmaceuticals (27) 27
hematology (27) 27
inflammatory bowel disease (27) 27
legislation, drug (27) 27
management (27) 27
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (689) 689
German (12) 12
Spanish (5) 5
Polish (3) 3
Portuguese (2) 2
Russian (2) 2
Swedish (2) 2
Chinese (1) 1
French (1) 1
Hungarian (1) 1
Italian (1) 1
Japanese (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10086, pp. 2304 - 2316
Journal Article
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 12/2015, Volume 112, Issue 50, pp. 15261 - 15262
Journal Article
Journal Article
Advances in Therapy, ISSN 0741-238X, 8/2015, Volume 32, Issue 8, pp. 742 - 756
Inflammatory autoimmune diseases (rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis) have a... 
Remicade | Psoriasis | Rheumatology | Internal Medicine | Oncology | Remsima | Biosimilar | Psoriatic arthritis | Medicine & Public Health | Infliximab | Rheumatoid arthritis | Cardiology | Pharmacology/Toxicology | Endocrinology | Ankylosing spondylitis | Crohn’s disease | Ulcerative colitis | MEDICINE, RESEARCH & EXPERIMENTAL | Remicade (R) | COST-EFFECTIVENESS | INNOVATOR INFLIXIMAB | CROHNS-DISEASE | ACTIVE RHEUMATOID-ARTHRITIS | Crohn's disease | ANKYLOSING-SPONDYLITIS | PSORIATIC-ARTHRITIS | PARALLEL-GROUP | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | Remsima (R) | QUALITY-OF-LIFE | NECROSIS-FACTOR INHIBITORS | Arthritis, Psoriatic - economics | Models, Econometric | Biosimilar Pharmaceuticals - therapeutic use | Europe | Humans | Spondylitis, Ankylosing - drug therapy | Infliximab - economics | Antibodies, Monoclonal - therapeutic use | Male | Biosimilar Pharmaceuticals - economics | Infliximab - therapeutic use | Spondylitis, Ankylosing - economics | Drug Costs - statistics & numerical data | Arthritis, Rheumatoid - drug therapy | Arthritis, Psoriatic - drug therapy | Antirheumatic Agents - economics | Female | Aged | Antibodies, Monoclonal - economics | Arthritis, Rheumatoid - economics | Cost Savings - statistics & numerical data | Prescription Fees - statistics & numerical data | Cost Savings - methods | Antirheumatic Agents - therapeutic use | Rheumatoid factor | Care and treatment | Analysis | Resveratrol | Budget | Autoimmune diseases | Original Research
Journal Article
18.